590 related articles for article (PubMed ID: 10879539)
1. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.
Stover CK; Warrener P; VanDevanter DR; Sherman DR; Arain TM; Langhorne MH; Anderson SW; Towell JA; Yuan Y; McMurray DN; Kreiswirth BN; Barry CE; Baker WR
Nature; 2000 Jun; 405(6789):962-6. PubMed ID: 10879539
[TBL] [Abstract][Full Text] [Related]
2. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.
Tyagi S; Nuermberger E; Yoshimatsu T; Williams K; Rosenthal I; Lounis N; Bishai W; Grosset J
Antimicrob Agents Chemother; 2005 Jun; 49(6):2289-93. PubMed ID: 15917523
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis.
Upton AM; Cho S; Yang TJ; Kim Y; Wang Y; Lu Y; Wang B; Xu J; Mdluli K; Ma Z; Franzblau SG
Antimicrob Agents Chemother; 2015 Jan; 59(1):136-44. PubMed ID: 25331696
[TBL] [Abstract][Full Text] [Related]
4. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.
Lenaerts AJ; Gruppo V; Marietta KS; Johnson CM; Driscoll DK; Tompkins NM; Rose JD; Reynolds RC; Orme IM
Antimicrob Agents Chemother; 2005 Jun; 49(6):2294-301. PubMed ID: 15917524
[TBL] [Abstract][Full Text] [Related]
5. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
6. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
7. New anti-tuberculosis drugs with novel mechanisms of action.
Rivers EC; Mancera RL
Curr Med Chem; 2008; 15(19):1956-67. PubMed ID: 18691051
[TBL] [Abstract][Full Text] [Related]
8. Molecule Property Analyses of Active Compounds for
Makarov V; Salina E; Reynolds RC; Kyaw Zin PP; Ekins S
J Med Chem; 2020 Sep; 63(17):8917-8955. PubMed ID: 32259446
[TBL] [Abstract][Full Text] [Related]
9. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
Matsumoto M; Hashizume H; Tomishige T; Kawasaki M; Tsubouchi H; Sasaki H; Shimokawa Y; Komatsu M
PLoS Med; 2006 Nov; 3(11):e466. PubMed ID: 17132069
[TBL] [Abstract][Full Text] [Related]
10. Delamanid Kills Dormant Mycobacteria
Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
[TBL] [Abstract][Full Text] [Related]
11. 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases.
Thompson AM; Blaser A; Palmer BD; Anderson RF; Shinde SS; Launay D; Chatelain E; Maes L; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
Bioorg Med Chem Lett; 2017 Jun; 27(11):2583-2589. PubMed ID: 28462832
[TBL] [Abstract][Full Text] [Related]
12. OPC-67683.
Tuberculosis (Edinb); 2008 Mar; 88(2):132-3. PubMed ID: 18486051
[No Abstract] [Full Text] [Related]
13. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.
Sasaki H; Haraguchi Y; Itotani M; Kuroda H; Hashizume H; Tomishige T; Kawasaki M; Matsumoto M; Komatsu M; Tsubouchi H
J Med Chem; 2006 Dec; 49(26):7854-60. PubMed ID: 17181168
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis.
Ashtekar DR; Costa-Perira R; Nagrajan K; Vishvanathan N; Bhatt AD; Rittel W
Antimicrob Agents Chemother; 1993 Feb; 37(2):183-6. PubMed ID: 8452346
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis.
Fujiwara M; Kawasaki M; Hariguchi N; Liu Y; Matsumoto M
Tuberculosis (Edinb); 2018 Jan; 108():186-194. PubMed ID: 29523322
[TBL] [Abstract][Full Text] [Related]
16. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
17. Novel Pyrimidines as Antitubercular Agents.
Inoyama D; Paget SD; Russo R; Kandasamy S; Kumar P; Singleton E; Occi J; Tuckman M; Zimmerman MD; Ho HP; Perryman AL; Dartois V; Connell N; Freundlich JS
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311070
[No Abstract] [Full Text] [Related]
18. Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
Palmer BD; Sutherland HS; Blaser A; Kmentova I; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA; Thompson AM
J Med Chem; 2015 Apr; 58(7):3036-59. PubMed ID: 25781074
[TBL] [Abstract][Full Text] [Related]
19. Biarylmethoxy 2-nitroimidazooxazine antituberculosis agents: Effects of proximal ring substitution and linker reversal on metabolism and efficacy.
Thompson AM; Blaser A; Palmer BD; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
Bioorg Med Chem Lett; 2015 Sep; 25(18):3804-9. PubMed ID: 26253632
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.
Rakesh ; Bruhn DF; Scherman MS; Singh AP; Yang L; Liu J; Lenaerts AJ; Lee RE
Bioorg Med Chem Lett; 2016 Jan; 26(2):388-391. PubMed ID: 26711150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
